Increased immunosuppressive treatment combined with unrelated umbilical cord blood infusion in children with severe aplastic anemia.
A combination treatment of unrelated umbilical cord blood (UCB) and increased immunosuppressive treatment (IST) were investigated to reveal the potentially curative therapy for the severe aplastic anemia (SAA). A total of 36 children (2-17 ages) with SAA who received UCB infusion after an IST were analyzed. The treatment consisted of 100mg/kg cyclophosphamide, 12.5-15 mg/kg antithymocyte globulin and 3mg/kg cyclosporine. After 3 months, the hematologic complete response (CR) rate was 22.2% and partial response (PR) rate was 38.9%. After 6 months, the CR rate and PR rate was 50.4% and 26.3%, respectively. The probability of 3-year survival was 83.3%. There was no difference in the survival rate either between the horse-ATG and rabbit-ATG or between the SAA and VSAA. The results indicated that the increased IST combined with unrelated UCB infusion has an effective therapeutic potential for children with SAA who lack of compatible donor for transplantation.
Department of Hematology, The General Hospital of Jinan Military District, Jinan, China.
Lin-na
LN
Xie
Department of Hematology, The General Hospital of Jinan Military District, Jinan, China.
Yuan
Y
Fang
Department of Hematology, The General Hospital of Jinan Military District, Jinan, China.
Zhe
Z
Yu
Department of Hematology, The General Hospital of Jinan Military District, Jinan, China.
Ning-xia
NX
Song
Department of Hematology, The General Hospital of Jinan Military District, Jinan, China.
Fan-sheng
FS
Kong
Department of Hematology, The General Hospital of Jinan Military District, Jinan, China.
Xi-min
XM
Liu
Department of Hematology, The General Hospital of Jinan Military District, Jinan, China. Electronic address: fangzhou223@hotmail.com.
Fang
F
Zhou
D000293:Adolescent; D000741:Anemia, Aplastic / Q000188:drug therapy / Q000628:therapy*; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D005312:Fetal Blood / Q000637:transplantation*; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D013534:Survival; D015996:Survival Rate; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003520:Cyclophosphamide
Increased immunosuppressive treatment; Severe aplastic anemia; Umbilical cord blood